Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Double-Blind Placebo-Controlled Study of NPC-06 in Trigeminal Neuralgia
jRCT2011220043Phase 3Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Apr 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in trigeminal neuralgia (TN) and Idiopathic Trigeminal Neuralgia (TN) comparing NPC-06 (fosphenytoin) IV with Placebo IV (2 arms). Primary endpoint: Primary: Change in NRS pain score at 120 minutes after first study drug administration. Started Apr 2023; status: completed.
02
Drugs
fosphenytoin
03
Conditions
trigeminal neuralgia (TN)Idiopathic Trigeminal Neuralgia (TN)
Beyond the preview
Go deeper on jRCT2011220043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220043.